Paul F Truex
CIK 1120362 · Executive Chaiman · last filed 2022-06-01
Paul F Truex is an Executive Chaiman who has filed 58 SEC Form 4 insider transactions across 4 companies since 2010. The most recent filing, for MIST, was dated Jun 1, 2022. Across all open-market trades the lifetime net is −$987.0K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.2K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ANTH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1751 HARBOR BAY PARKWAY
ALAMEDA, CA 94502
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MIST | Director | 8,016 | $0.64 | $5.2K | $28.0K | 4 | 2022-06-01 |
| CymaBay Therapeutics, Inc. (CBAY) Delisted | Director | — | $32.48 | — | $0 | 8 | 2021-01-28 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Executive Chaiman | 17,419 | — | — | -$1.03M | 39 | 2018-01-09 |
| Trius Therapeutics Inc (TSRX) Delisted | Director | 13,270 | — | — | $17.1K | 6 | 2013-05-23 |
Recent Filings
58 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-01 | MIST | Mixed | +81,780 | $143.8K | EDGAR |
| 2021-07-29 | MIST | Grant (A) | — | $0 | EDGAR |
| 2021-01-28 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-08 | MIST | Grant (A) | — | $0 | EDGAR |
| 2020-05-19 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-11-14 | MIST | Grant (A) | — | $0 | EDGAR |
| 2019-01-31 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-26 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-09 | Anthera Pharmaceuticals Inc (ANTH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-09-26 | CymaBay Therapeutics, Inc. (CBAY) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.